Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

NCT00450970 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
344
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decided to discontinue study drug development.

Conditions

Interventions

Sponsor

Agennix